Henlius' Hansizhuang (serplulimab) Receives NMPA’s Approval for the Treatment of Squamous Non-Small Cell Lung Cancer
Shots:
- The NMPA has approved Hansizhuang + carboplatin and albumin-bound paclitaxel for unresectable LA or metastatic sq. NSCLC
- The approval was based on the P-III (ASTRUM-004) trial which has been initiated in many countries globally incl. China, Poland, Turkey, etc. The results indicated that the combination therapy can provide significant benefits for prior sqNSCLC patients
- The therapy was approved for MSI-H solid tumors and covers a wide variety of indications for benefiting a broader population of patients. The company has initiated many clinical studies, incl. Hansizhuang in combination with HLX07 for sqNSCLC with EGFR overexpression & in combination with bevacizumab as 1L treatment of nsqNSCLC
Ref: PRNewswire | Image: Henlius
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
